Celgene Corporation

Amgen Inc.

Celgene International Ii Sarl

Peter Henry Schafer

George W Muller

Hon-Wah Man

Chuansheng Ge

Anita Gandhi

Jean Xu

Ying Ye

Rajesh Chopra

Lei Wu

Antonia Lopez-Girona

Thomas O Daniel

Derek Mendy

Anthony Frank

Laura Corral

Patricia E W Rohane

Sai Shankar

Henry Chan

Garth E Ringheim

Lisa Beebe

Justin Blake Bartlett

Angus Dalgleish

Christine Galustian

Roli Khattri

Monica Leung

Pilgrim Jackson

Laura G Corral

Maria Yinglin Wang

Ling-Hua Zhang

Tiffany Carr

Brendan Meyer

Te-chen Tzeng

Eun Mi Hur

Shaojun Tang

Mary Adams

Donna J Sutherland

Robert Plenge

Matthew William Burnell Trotter

Shimon Korish

Gilles Buchwalter

Lori Capone

Justin B Bartlett

Yong Lin

Donna Sutherland

Angus C Dalgleish

Justin B Bertlett

Christine Galutian

Angus G Dalgleish

A method of determining a dose of a treatment compound for treating a subject having systemic lupus erythematosus (SLE), comprising obtaining a sample from the subject and measuring the gene expression level of IKZF3 and/or the gene expression levels of IFI27, IFI44, IFI44L, and RSAD2 in the sample.

Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies

Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE). Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

Treatment of immune-related and inflammatory diseases

Provided herein are methods of treating diseases and disorder responsive to the inhibition of PDE4 comprising administering apremilast and a Tyk2 inhibitor to a subject. Also provided herein are pharmaceutical compositions comprising apremilast and a Tyk2 inhibitor.

Combination therapies comprising apremilast and Tyk2 inhibitors

Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (&#x2212;) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-&#x3b1; or the inhibition of PDE4.

(+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof

Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione

Provided herein are methods for managing, treating, or preventing immune disorders, such as autoimmune diseases, using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.

Methods of treating psoriasis using PD-1 binding antibodies

Methods of using (+)- 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1, 3-dione

3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

Stereomerically pure (+)-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (&#x2212;) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-&#x3b1; or the inhibition of PDE4.

Uses of the protein cereblon as a predictor of clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.

Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor

Provided herein are methods for predicting the clinical sensitivity of an inflammatory disease (e.g., ankylosing spondylitis) and a subject's response to treatment with apremilast using the level of a biomarker (e.g., MCP1). Also provided herein are methods for treating an inflammatory disease.

Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilast

Growing community of inventors

Belle Mead, NJ, United States of America

Peter Henry Schafer